Kamada (KMDA) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KMDA shares.
View KMDA analyst ratings or view top-rated stocks.

1 brokerages have issued 1-year price objectives for Kamada's stock. Their KMDA share price forecasts range from $11.00 to $11.00. On average, they predict the company's share price to reach $11.00 in the next year. This suggests a possible upside of 120.9% from the stock's current price.
View analysts price targets for KMDA or view top-rated stocks among Wall Street analysts.

Kamada's stock was trading at $4.01 on January 1st, 2023. Since then, KMDA stock has increased by 24.2% and is now trading at $4.98.
View the best growth stocks for 2023 here.

Kamada saw a decline in short interest in May. As of May 15th, there was short interest totaling 5,400 shares, a decline of 60.6% from the April 30th total of 13,700 shares. Based on an average trading volume of 20,300 shares, the short-interest ratio is currently 0.3 days. Approximately 0.0% of the shares of the stock are sold short.
View Kamada's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 16th 2023.
View our KMDA earnings forecast.

Kamada Ltd. (NASDAQ:KMDA) announced its earnings results on Wednesday, March, 15th. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.04. The biotechnology company had revenue of $45.44 million for the quarter, compared to analyst estimates of $44.64 million. Kamada had a positive trailing twelve-month return on equity of 8.15% and a negative net margin of 1.74%.

Kamada issued an update on its FY 2023 earnings guidance on Friday, May, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $138.00 million-$146.00 million, compared to the consensus revenue estimate of $141.36 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Micron Technology (MU), Teva Pharmaceutical Industries (TEVA) and Aegean Marine Petroleum Network (ANW).

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

Kamada's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.89%), Acadian Asset Management LLC (1.44%), Altshuler Shaham Ltd (0.79%), Meitav Investment House Ltd. (0.15%) and UBS Group AG (0.11%).

Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KMDA stock can currently be purchased for approximately $4.98.

Kamada (NASDAQ:KMDA) has a market capitalization of $223.20 million and generates $129.34 million in revenue each year. The biotechnology company earns $-2,320,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis.

The company employs 355 workers across the globe.

Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The official website for the company is www.kamada.com. The biotechnology company can be reached via phone at (728) 940-6472, via email at ir@kamada.com, or via fax at 972-8940-6473.